151 related articles for article (PubMed ID: 37023368)
41. PTPN2 negatively regulates oncogenic JAK1 in T-cell acute lymphoblastic leukemia.
Kleppe M; Soulier J; Asnafi V; Mentens N; Hornakova T; Knoops L; Constantinescu S; Sigaux F; Meijerink JP; Vandenberghe P; Tartaglia M; Foa R; Macintyre E; Haferlach T; Cools J
Blood; 2011 Jun; 117(26):7090-8. PubMed ID: 21551237
[TBL] [Abstract][Full Text] [Related]
42. STAT5 is essential for IL-7-mediated viability, growth, and proliferation of T-cell acute lymphoblastic leukemia cells.
Ribeiro D; Melão A; van Boxtel R; Santos CI; Silva A; Silva MC; Cardoso BA; Coffer PJ; Barata JT
Blood Adv; 2018 Sep; 2(17):2199-2213. PubMed ID: 30185437
[TBL] [Abstract][Full Text] [Related]
43. Mutation of the receptor tyrosine phosphatase PTPRC (CD45) in T-cell acute lymphoblastic leukemia.
Porcu M; Kleppe M; Gianfelici V; Geerdens E; De Keersmaecker K; Tartaglia M; Foà R; Soulier J; Cauwelier B; Uyttebroeck A; Macintyre E; Vandenberghe P; Asnafi V; Cools J
Blood; 2012 May; 119(19):4476-9. PubMed ID: 22438252
[TBL] [Abstract][Full Text] [Related]
44. Either IL-7 activation of JAK-STAT or BEZ inhibition of PI3K-AKT-mTOR pathways dominates the single-cell phosphosignature of
Kuzilková D; Bugarin C; Rejlova K; Schulz AR; Mei HE; Paganin M; Biffi A; Biondi A; Kalina T; Gaipa G
Haematologica; 2022 Jun; 107(6):1293-1310. PubMed ID: 34670357
[TBL] [Abstract][Full Text] [Related]
45. Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities.
Losdyck E; Hornakova T; Springuel L; Degryse S; Gielen O; Cools J; Constantinescu SN; Flex E; Tartaglia M; Renauld JC; Knoops L
J Biol Chem; 2015 Nov; 290(48):29022-34. PubMed ID: 26446793
[TBL] [Abstract][Full Text] [Related]
46. The T-cell leukemia-associated ribosomal RPL10 R98S mutation enhances JAK-STAT signaling.
Girardi T; Vereecke S; Sulima SO; Khan Y; Fancello L; Briggs JW; Schwab C; de Beeck JO; Verbeeck J; Royaert J; Geerdens E; Vicente C; Bornschein S; Harrison CJ; Meijerink JP; Cools J; Dinman JD; Kampen KR; De Keersmaecker K
Leukemia; 2018 Mar; 32(3):809-819. PubMed ID: 28744013
[TBL] [Abstract][Full Text] [Related]
47. IL-7: Comprehensive review.
Winer H; Rodrigues GOL; Hixon JA; Aiello FB; Hsu TC; Wachter BT; Li W; Durum SK
Cytokine; 2022 Dec; 160():156049. PubMed ID: 36201890
[TBL] [Abstract][Full Text] [Related]
48. NOTCH1 activation clinically antagonizes the unfavorable effect of PTEN inactivation in BFM-treated children with precursor T-cell acute lymphoblastic leukemia.
Bandapalli OR; Zimmermann M; Kox C; Stanulla M; Schrappe M; Ludwig WD; Koehler R; Muckenthaler MU; Kulozik AE
Haematologica; 2013 Jun; 98(6):928-36. PubMed ID: 23349303
[TBL] [Abstract][Full Text] [Related]
49. TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia.
Sanda T; Tyner JW; Gutierrez A; Ngo VN; Glover J; Chang BH; Yost A; Ma W; Fleischman AG; Zhou W; Yang Y; Kleppe M; Ahn Y; Tatarek J; Kelliher MA; Neuberg DS; Levine RL; Moriggl R; Müller M; Gray NS; Jamieson CH; Weng AP; Staudt LM; Druker BJ; Look AT
Cancer Discov; 2013 May; 3(5):564-77. PubMed ID: 23471820
[TBL] [Abstract][Full Text] [Related]
50. Current and emerging therapeutic approaches for T-cell acute lymphoblastic leukaemia.
Pocock R; Farah N; Richardson SE; Mansour MR
Br J Haematol; 2021 Jul; 194(1):28-43. PubMed ID: 33942287
[TBL] [Abstract][Full Text] [Related]
51. Adult T-cell acute lymphoblastic leukemias with IL7R pathway mutations are slow-responders who do not benefit from allogeneic stem-cell transplantation.
Kim R; Boissel N; Touzart A; Leguay T; Thonier F; Thomas X; Raffoux E; Huguet F; Villarese P; Fourrage C; Passini L; Hunault M; Lepretre S; Chevallier P; Braun T; Lhéritier V; Chantepie S; Maury S; Escoffre M; Tavernier E; Chalandon Y; Graux C; Macintyre E; Ifrah N; Asnafi V; Dombret H; Lhermitte L;
Leukemia; 2020 Jul; 34(7):1730-1740. PubMed ID: 31992840
[TBL] [Abstract][Full Text] [Related]
52. Mutant IL-7Rα and mutant NRas are sufficient to induce murine T cell acute lymphoblastic leukemia.
Cramer SD; Hixon JA; Andrews C; Porter RJ; Rodrigues GOL; Wu X; Back T; Czarra K; Michael H; Cam M; Chen J; Esposito D; Senkevitch E; Negi V; Aplan PD; Li W; Durum SK
Leukemia; 2018 Aug; 32(8):1795-1882. PubMed ID: 29535426
[No Abstract] [Full Text] [Related]
53. Single-cell profiling of pediatric T-cell acute lymphoblastic leukemia: Impact of PTEN exon 7 mutation on PI3K/Akt and JAK-STAT signaling pathways.
Bonaccorso P; Bugarin C; Buracchi C; Fazio G; Biondi A; Lo Nigro L; Gaipa G
Cytometry B Clin Cytom; 2020 Nov; 98(6):491-503. PubMed ID: 32479694
[TBL] [Abstract][Full Text] [Related]
54. Targeting cytokine- and therapy-induced PIM1 activation in preclinical models of T-cell acute lymphoblastic leukemia and lymphoma.
De Smedt R; Morscio J; Reunes L; Roels J; Bardelli V; Lintermans B; Van Loocke W; Almeida A; Cheung LC; Kotecha RS; Mansour MR; Uyttebroeck A; Vandenberghe P; La Starza R; Mecucci C; Lammens T; Van Roy N; De Moerloose B; Barata JT; Taghon T; Goossens S; Van Vlierberghe P
Blood; 2020 May; 135(19):1685-1695. PubMed ID: 32315407
[TBL] [Abstract][Full Text] [Related]
55. Overcoming Steroid Resistance in Pediatric Acute Lymphoblastic Leukemia-The State-of-the-Art Knowledge and Future Prospects.
Kośmider K; Karska K; Kozakiewicz A; Lejman M; Zawitkowska J
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409154
[TBL] [Abstract][Full Text] [Related]
56. Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia.
Degryse S; de Bock CE; Demeyer S; Govaerts I; Bornschein S; Verbeke D; Jacobs K; Binos S; Skerrett-Byrne DA; Murray HC; Verrills NM; Van Vlierberghe P; Cools J; Dun MD
Leukemia; 2018 Mar; 32(3):788-800. PubMed ID: 28852199
[TBL] [Abstract][Full Text] [Related]
57. JAK/BCL2 inhibition acts synergistically with LSD1 inhibitors to selectively target ETP-ALL.
Benyoucef A; Haigh K; Cuddihy A; Haigh JJ
Leukemia; 2022 Dec; 36(12):2802-2816. PubMed ID: 36229595
[TBL] [Abstract][Full Text] [Related]
58. CSL-MAML-dependent Notch1 signaling controls T lineage-specific IL-7R{alpha} gene expression in early human thymopoiesis and leukemia.
González-García S; García-Peydró M; Martín-Gayo E; Ballestar E; Esteller M; Bornstein R; de la Pompa JL; Ferrando AA; Toribio ML
J Exp Med; 2009 Apr; 206(4):779-91. PubMed ID: 19349467
[TBL] [Abstract][Full Text] [Related]
59. Interleukin-7 receptor-α gene mutations are not detected in adult T-cell acute lymphoblastic leukemia.
Rozovski U; Li P; Harris D; Ohanian M; Kantarjian H; Estrov Z
Cancer Med; 2014 Jun; 3(3):550-4. PubMed ID: 24678068
[TBL] [Abstract][Full Text] [Related]
60. The Notch driven long non-coding RNA repertoire in T-cell acute lymphoblastic leukemia.
Durinck K; Wallaert A; Van de Walle I; Van Loocke W; Volders PJ; Vanhauwaert S; Geerdens E; Benoit Y; Van Roy N; Poppe B; Soulier J; Cools J; Mestdagh P; Vandesompele J; Rondou P; Van Vlierberghe P; Taghon T; Speleman F
Haematologica; 2014 Dec; 99(12):1808-16. PubMed ID: 25344525
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
